人单克隆抗体治疗HBV感染的研究进展

IF 5.7 2区 医学 Q1 VIROLOGY Current opinion in virology Pub Date : 2022-04-01 DOI:10.1016/j.coviro.2022.101205
Maxime Beretta , Hugo Mouquet
{"title":"人单克隆抗体治疗HBV感染的研究进展","authors":"Maxime Beretta ,&nbsp;Hugo Mouquet","doi":"10.1016/j.coviro.2022.101205","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>HBV neutralizing antibodies target the </span>viral envelope antigens (HBsAg) and confer long-term immune protection in vaccinees and infected humans who seroconvert. They recognize various HBsAg epitopes, and can be armed with Fc-dependent effector functions essential for eliminating infected cells and stimulating </span>adaptive immunity<span>. Hundreds of HBsAg-specific monoclonal antibodies (mAbs) were produced from the early 80’s, but it is only recently that </span></span><em>bona fide</em> human anti-HBV mAbs were generated from vaccinees and seroconverters. Neutralizing HBV mAbs have <em>in vivo</em><span> prophylactic and therapeutic efficacy in animal models, and the capacity to decrease antigenemia and viremia<span> in infected humans. Thus, polyfunctional, potent and broad human HBV neutralizing mAbs offer novel opportunities to develop effective interventions to prevent and treat HBV infection. Here, we summarize recent findings on the humoral immune response to HBV, and explore the potential of human HBV neutralizing mAbs as immunotherapeutics to help achieving a functional cure for HBV.</span></span></p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"Advances in human monoclonal antibody therapy for HBV infection\",\"authors\":\"Maxime Beretta ,&nbsp;Hugo Mouquet\",\"doi\":\"10.1016/j.coviro.2022.101205\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span>HBV neutralizing antibodies target the </span>viral envelope antigens (HBsAg) and confer long-term immune protection in vaccinees and infected humans who seroconvert. They recognize various HBsAg epitopes, and can be armed with Fc-dependent effector functions essential for eliminating infected cells and stimulating </span>adaptive immunity<span>. Hundreds of HBsAg-specific monoclonal antibodies (mAbs) were produced from the early 80’s, but it is only recently that </span></span><em>bona fide</em> human anti-HBV mAbs were generated from vaccinees and seroconverters. Neutralizing HBV mAbs have <em>in vivo</em><span> prophylactic and therapeutic efficacy in animal models, and the capacity to decrease antigenemia and viremia<span> in infected humans. Thus, polyfunctional, potent and broad human HBV neutralizing mAbs offer novel opportunities to develop effective interventions to prevent and treat HBV infection. Here, we summarize recent findings on the humoral immune response to HBV, and explore the potential of human HBV neutralizing mAbs as immunotherapeutics to help achieving a functional cure for HBV.</span></span></p></div>\",\"PeriodicalId\":11082,\"journal\":{\"name\":\"Current opinion in virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2022-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1879625722000128\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879625722000128","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 12

摘要

HBV中和抗体靶向病毒包膜抗原(HBsAg),并在疫苗接种者和血清转化的感染者中给予长期免疫保护。它们可以识别各种HBsAg表位,并具有fc依赖的效应功能,这些功能对于消除感染细胞和刺激适应性免疫至关重要。从上世纪80年代初开始,就生产出了数百种hbsag特异性单克隆抗体(mab),但直到最近,才从疫苗接种者和血清转化者身上生产出真正的人抗hbv单克隆抗体。中和型HBV单克隆抗体在动物模型中具有体内预防和治疗效果,并能减少感染者的抗原血症和病毒血症。因此,多功能、强效和广泛的人HBV中和单克隆抗体为开发预防和治疗HBV感染的有效干预措施提供了新的机会。在这里,我们总结了对HBV的体液免疫反应的最新发现,并探索了人类HBV中和单克隆抗体作为免疫治疗药物的潜力,以帮助实现HBV的功能性治愈。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Advances in human monoclonal antibody therapy for HBV infection

HBV neutralizing antibodies target the viral envelope antigens (HBsAg) and confer long-term immune protection in vaccinees and infected humans who seroconvert. They recognize various HBsAg epitopes, and can be armed with Fc-dependent effector functions essential for eliminating infected cells and stimulating adaptive immunity. Hundreds of HBsAg-specific monoclonal antibodies (mAbs) were produced from the early 80’s, but it is only recently that bona fide human anti-HBV mAbs were generated from vaccinees and seroconverters. Neutralizing HBV mAbs have in vivo prophylactic and therapeutic efficacy in animal models, and the capacity to decrease antigenemia and viremia in infected humans. Thus, polyfunctional, potent and broad human HBV neutralizing mAbs offer novel opportunities to develop effective interventions to prevent and treat HBV infection. Here, we summarize recent findings on the humoral immune response to HBV, and explore the potential of human HBV neutralizing mAbs as immunotherapeutics to help achieving a functional cure for HBV.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.80
自引率
5.10%
发文量
76
审稿时长
83 days
期刊介绍: Current Opinion in Virology (COVIRO) is a systematic review journal that aims to provide specialists with a unique and educational platform to keep up to date with the expanding volume of information published in the field of virology. It publishes 6 issues per year covering the following 11 sections, each of which is reviewed once a year: Emerging viruses: interspecies transmission; Viral immunology; Viral pathogenesis; Preventive and therapeutic vaccines; Antiviral strategies; Virus structure and expression; Animal models for viral diseases; Engineering for viral resistance; Viruses and cancer; Virus vector interactions. There is also a section that changes every year to reflect hot topics in the field.
期刊最新文献
Advancing zoonotic respiratory virus research through the use of organoids. Editorial Board Koala retrovirus and neoplasia: correlation and underlying mechanisms Modeling zoonotic and vector-borne viruses Oncogenic Animal Herpesviruses
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1